ABSTRACT

Background
Exogenous cytokine and neuropeptide regulation or "modulation" of the immune system has been the subject of much research over the last decade. It is well known that various peptides influence lymphocyte and macrophage activity by either suppressing or enhancing certain functions. The purpose of this double blind clinical trial is to more clearly illuminate immune pathways that the refined lacteal complex Ai/E¹®, considered an immune modulator, may affect. An immune modulator should affect multiple aspects of immune function as opposed to merely, as an example, providing stimulation.

Study Design
Twenty (20) subjects, ten women and ten men, ranging in age from 32 to 61 years participated in the study. Each of them had a series of laboratory blood tests designed to measure the structure and functional capacity of the immune system at the start of the study.

Ten (10) subjects received 200 mg of Ai/E¹® three times a day for fifteen (15) days. The other ten (10) subjects received a capsule of a placebo (calcium carbonate) three times a day for fifteen (15) days. After the 15 days, the laboratory blood tests were repeated for comparison.

Results
Seven of the ten (10) participants that received Ai/E¹® had a significant increase in three major immune markers; Natural Killer (NK) cell, Tumor Necrosis Factor (TNF) and Phagocytic Index (PI) or macrophage activity. Three participants had no change in the markers.

Five of the ten (10) participants in the control group had an increase in TNF, four had an increase in NK cell function and four had an increase in PI. Of this group there was decrease in function for three participants in TNF, five participants in NK function and five participants in PI.

Three participants had no change in the three markers.

Increases and decreases in marker values can be viewed in patterns that may have some significance in monitoring immune modulation.

Findings
This study provides some preliminary indications that suggest that Ai/E¹® contains cytokines, peptide neurohormones and other informational molecules associated with modulated and normalized immune function and may enhance leukocyte anti-infective and cyto-toxic activities. There was no evidence of an increase in detrimental inflammatory cytokine production and circulating APC macrophages increased within a range of normal immune function. This "selective" activity is consistent with a modulatory activity and illustrates the potential of Ai/E¹® to function as a "Biological Immune Response Modulator" that could help sustain the protective functions of the immune system.
An Examination of Immune Response Modulation in Humans by Ai/E¹º® Utilizing A Double Blind Study
Immune Consultants, Inc., Tucson, Arizona, January 2001

Background
Exogenous cytokine and neuropeptide regulation of the immune system has been the subject of much research over the last decade. Various peptides are known to influence lymphocyte and macrophage activity by either suppressing or enhancing certain functions. Some of these pathways are understood and defined while many remain undefined. Refined lacteal complexes such as Ai/E¹º® have been in veterinary and human use in various forms for over 40 years.

One clinically observed effect of Ai/E¹º® has been increases in Natural Killer (NK) cell activity with an associated increase in the production of cyto-toxic reactive oxygen intermediates. The purpose of this double blind clinical study was to more clearly elucidate the immune pathways that the material may be affecting and thereby enable more decisive clinical application in the future.

Since 1993 thousands of people have used and continue to use Ai/E¹º® as a dietary supplement. Many of these people have reported experiencing health benefits that they attribute to the material. Clinical studies on patient populations suffering from degenerative and chronic disease have provided consistent and dramatic documentation of increases in NK cell activity. This empirical evidence and clinical study data suggest and demonstrate an immune modulation effect associated with the material in combination with other nutrients, as well as the safety of Ai/E¹º®. This is the first double blind clinical study using only Ai/E¹º® with a healthy population.

Ai/E¹º® can only be produced under the most unique circumstances. All of the key factors came together in 1993 and the material became available for humans for the first time. In the late 1940’s and early 1950’s university professors and biochemists began to explore the observable benefits of bovine lacteal secretions. By the early 1970’s, bovine colostrum was being touted as a replacement strategy for antibiotics. However, the apparent effectiveness and simplicity of manufacturing antibiotics led to the exclusion of further consideration of lacteal secretion extracts and perhaps other options.

Though many were aware in the 1970’s, all of us have recently become sensitive to the fact that antibiotics present serious side effects and consequences not fully acknowledged in the 1970’s. We now have organisms that live on antibiotics and diseases that we cannot control. Many antibiotics are immune suppressive, turning-off the only defense system that we have to protect our health. In fact, many pharmaceutical products are also immune suppressive.

The laboratory tests needed to study the effects of Ai/E¹º® became available in
the mid 1990’s. Unlike colostrum or whey, Ai/E¹º® is a bio-engineered extract that requires very controlled conditions in order to obtain the desired product. Several key factors must be in place for the manufacturing of Ai/E¹º® to commence:

1. A privately managed herd of dairy cows.
2. A managed breeding program to optimize and select for specific immune responses.
3. An effective strategy for antigen stimulation. Only a process known as infusion has been demonstrated consistently and reliably effective in nearly 50 years of study (U.S. Patent #4,402,938).
4. The ability to identify, purify, recover and concentrate sufficient quantities of the immunological factors necessary to cause all of the observed changes to take place.

Safety
Many millions of servings of Ai/E¹º® have been taken without any observed or reported adverse or allergic reactions.

Study Participant Eligibility Criteria
The following eligibility criteria were applied to human subjects for this double-blind study.

- They were between the ages of 21 and 65.
- They were not be suffering from any known severe or chronic diseases, were not experiencing any unusual high stress circumstances, not taking any pharmaceutical medications, were non-smokers and could not be pregnant.

For agreeing to participate in this clinical study each participant received a six months supply of a currently manufactured and distributed product that included Ai/E¹º®.

Study Design
Twenty (20) subjects were included in the study and each of them had a series of laboratory blood tests prior to starting the study (Appendix 1). Ten (10) subjects received 200 mg of Ai/E¹º® three times a day for fifteen (15) days. The other ten (10) subjects received a capsule of the placebo (calcium carbonate) three times a day for fifteen (15) days.

Neither the subjects nor the principle investigator knew which of the subjects were taking the placebo or the Ai/E¹º®. After the 15 days, the laboratory studies were repeated for comparison evaluation. The blood test evaluations included a variety of immunological tests designed to measure the structure and functional capacity of the immune system.
The actual patient population studied was as follows:

- Four (4) men and six (6) women in the group that received Ai/E¹º®.
- Six (6) men and four (4) women in the control group that received the placebo.
- Ages ranged from 32 to 61.

**Materials**

Ai/E¹º® is a specially prepared refined lacteal complex. The product is processed to preserve immuno-regulatory molecules. The material is then lyophilized and mixed with flowing agents, encapsulated and bottled.

**Natural Killer (NK) Cell Function Assay**

Natural Killer (NK) Cells are an important line of cyto-lytic defense. They are a distinct group of circulating mononuclear lymphocytes with no immunological memory and are independent of the adaptive immune system. NK cells typically constitute 5 to 16 percent of the total lymphocyte population. They mediate non-MHC restricted cyto-lytic activity without prior sensitization. They are distinguishable from T or B-lymphocytes by their surface phenotype and cytokine profile.

Currently, the standard test for NK cell activity or function is a cyto-toxicity assay using Cr51 labeled targets. K562 cells (2X10¹⁶) in CM are labeled with 350 uCi radioactive sodium chromate (Cr51) for 1 hr at 37 degrees Centigrade and 5% CO2. The labeled cells were washed twice in PBS, re-suspended and adjusted to 1X10⁵ cells/ml CM.

Subsequently in the study, duplicates of 1X10⁴ target cells in 100 ul were added to the effector cells in 96-well U-bottomed plates yielding E:T ratios of 50:1-1.5:1. The plates were centrifuged at 200Xg for 1 minute and incubated for 4 hr at 37 degrees Centigrade in the presence of 5% CO2. Spontaneous release was measured from the wells containing the target cells and medium and maximum release from wells containing target cells and 0.1% Triton X-100. After incubation, the plates were centrifuged at 200Xg for 5 min, 40-ul supernatant was harvested from each well into wells of MicroBeta Plus standard plates and 15ul of super scintillation cocktail were added. Emitted radioactivity was measured in a 1450 Micro Beta Plus scintillation counter. Percentage specific release of Cr51 was calculated as follows:

- \[100 \times \frac{cpm(test) - cpm(spontaneous)}{cpm(max) - cpm(spontaneous)}\]

**Neutrophil Phagocytosis (PI)**

The term macrophage is used to define a ubiquitous population of large mononuclear cells that have the ability to engulf and destroy particulate matter that it deems to be foreign or debris. Macrophages are the tissue equivalent of monocytes and are involved at all stages of the immune response. They act as rapid, first line protection, which can respond before T cell-mediated amplification
has taken place. Activated macrophages play a key role in host defense.

When monocytes enter the tissues and become macrophages they undergo several changes. The cells enlarge and increase the amount of intracellular lysozymes allowing greater phagocytosis. In the tissues, macrophages live for months or years and may be motile.

The flow cytometric assay of Phagocytic Index measures neutrophil-associated fluorescence after incubation of leukocytes with fluorescent micro spheres at both 4 degrees Centigrade and 37 degrees Centigrade. The index value represents the quotient of reactivity at 4 degrees Centigrade (adherence only). A deceased Phagocytic Index is indicative of impaired phagocyte function.

**Tumor Necrosis Factor (TNF)**

Tumor necrosis factors are pheliotropic cytokines that are considered primary modifiers of inflammatory and immune reactions. Tumor necrosis factor-a (cachectin) and tumor necrosis factor-B (lymphotoxin) are two closely related proteins that share sequence homology of 34% in their amino acid sequence. Both mediators act on their target cells via the same receptors and therefore show many similar, but not identical, biological effects. Many different cells are shown to produce TNF including CD4+ T-cells, smooth muscle cells, polymorphonuclear neutrophils, astrocytes, etc.

Due to the occurrence of TNF receptors on nearly all cells, TNF shows a wide variety of biological actions. It has cytolytic and cytostatic effects and shows chemotactic activity on neutrophils. TNF enhances the proliferation of T-cells after stimulation with IL-2. In the absence of IL-2, TNF induces the proliferation and differentiation of B cells.

TNF levels were analyzed with the Immulite® assay. Immulite® is a solid-phase, two-site chemiluminescent immunometric assay. The solid phase, a polystyrene bead enclosed within an Immulite test unit, is coated with a monoclonal antibody specific for TNF. While the patient sample and alkaline phosphatase-conjugated polyclonal anti-TNF antibody are incubated for 60 minutes at 37 degrees Centigrade in the test unit with intermittent agitation, TNF in the sample is bound to form an antibody sandwich complex. Unbound conjugate is then removed by a centrifugal wash, after which substrate is added and the test unit is incubated for a further 10 minutes.

The chemiluminescent substrate, a phosphate ester of adamantly dioxetane, undergoes hydrolysis in the presence of alkaline phosphatase to yield an unstable intermediate. The continuous production of the intermediate results in the sustained emission of light, thus improving precision by providing a window for multiple readings. The bound complex - and thus also the photon output, as measured by the illuminometer - is proportional to the concentration of the TNF in the sample.
Results
Of the ten patients in the group that received the Ai/E10® (Group A) seven had a significant increase in all three of the immune markers, NK cell, TNF and PI (macrophage) activity. Of this group, 1 person decreased TNF activity, 3 decreased in NK activity and 2 decreased in macrophage activity. Three participants had no change in the markers. These are highly significant changes reflecting a dramatic increase in immune system function and modulation within the fifteen-day period of the clinical trial. Note that two people in this group were found to have significant immune system compromises, after completing the blood tests and entering the study that were unknown to them.

In the control, or placebo, group (Group B), 5 participants had an increase in TNF, 4 had an increase in NK function and 4 had an increase in PI. Of this group there was a decrease in function for 3 participants in TNF, 5 participants in NK function and 5 participants in PI. Three participants had no change in the three markers. These results reflect typical responses from a population that is not receiving specific intervention to enhance immune system function.

This chart presents the net changes in each category of measurement. Quantitative changes are not particularly significant in viewing the activity of NK cells, TNF and macrophages in short term studies as the quantity of increases will vary from individual to individual. The three markers are in a state of flux towards increased immune function and modulation in Group A and in random state of change in Group B.

Increases and decrease in marker values can be viewed in patterns that may have some significance in monitoring immune modulation. Patterns have implications in long-term studies and may not be so relevant in short term studies. However, this study did reveal a pattern that is pointing towards the improved function and immune modulation effects of this immune response modulator.
In Group A there were two distinct patterns that were peculiar to that group. Three participants had increases of all three markers and one participant had an increase in NK activity and no change in the other two markers. In both groups there was a mixture of increases and decreases in random patterns however there were three patterns distinct for four Group B participants that showed a decrease in one or more of the three markers.

Immune system modulation is not present when the marker values are below normal or out of balance with each other. When an immune system response modulator is effective there is a change in the quantities of the individual markers with all, eventually, moving into normal ranges if the immune system is not compromised in function to the point where this is not possible. The movement of TNF and PI are much less than NK cell activity as the reference ranges for those two markers are much narrower than the NK cell activity range. However, the movement of all three markers into a high normal range is expected to occur in time with the administration of an effective immune response modulator that modulates the immune system.

**Findings**

An effective immune system response involves all aspects and components of the immune system from macrophage activation to T-8 cell suppression. Stimulation affects specific immune reactions but is lacking in expression of proper immune modulation. Immuno-modulatory reactions cause activity in the immune system that can be monitored, but not predicted, until the final states that are reflected in the activity of NK cells, macrophages and TNF. These three immune system markers largely indicate the state of modulation that is occurring in the milieu of the actions and reactions that cascade from immune system response to immune system homeostasis.

In monitoring the immune system “behind” the NK, TNF and PI markers we see an array of changes that reflect the processes of modulation. B cell activity will increase and decrease in predictable patterns and the production of antibodies vary accordingly. T lymphocytes are activated at regular intervals and the production of cytokines is appropriately responsive effecting related changes in immune function.

Synthetic stimulation of the immune system will often cause a change in one of the markers but will not reflect a modulation effect. Consequently, there is a limited effect on immune function. This is evident in the activation of NK cells.

NK cell activity can be increased readily by a number of natural or nutritional substances including some vitamins, herbs and minerals. However, increasing NK cell activity alone has very limited value if immune modulation is not achieved. B cell stimulation, as initiated by substances such as transfer factor, is
a good example of partial immune system activation without immuno-modulation and has thus proved to be of limited clinical value.

Drugs or any substance or influence that stimulates the immune system without having a balancing effect on the immune system is severely limited in its value as compared to immune modulation. The immune system must be in a state of modulation (dynamic equilibrium) to function optimally, which makes immune modulation critical to sustaining good health.

The study presents a double blind clinical trial illustrating that cytokines, peptide neurohormones and other informational molecules in Ai/E¹º® modulate and normalize immune function and is thus an orally effective biological immune response modulator for increasing the protective functions of the immune system.

This study investigated the immuno-modulatory effect of Ai/E¹º® on the human immune system in vivo. Many attempts are under way to find new - artificial or natural - immune response modifiers or modulators that can modulate immune function and lead to a successful counterattack against the consequences of biological entropy.

Traditionally, the battle plan has been focused upon T-cells and utilized molecular biological models in which various compounds have either increased or decreased some aspect of immune function. This paradigm utilizes analytical methods of cell and molecular biology e.g. lymphocyte sub-population response monitoring, NK function and quantitative levels, mitogen lectin proliferation, cytokine assays and the like are but merely an inadequate reflection of the flexible, complex, information processing system that the immune system represents.

Some researchers have likened the data obtained by this sort of testing as analogous to the data acquired by the electroencephalograph (EEG) machine when doing research about the brain. Such data can provide valuable information as to whether the brain is dead or alive, but the qualitative functions of the brain, intelligence, and the expression of emotions or the creation of a sonata can never be ascertained from such quantitative information.

What’s ultimately important about the human immune system is not just the numbers describing its activity, but that aspect of the wisdom of the body that we can refer to as "immune intelligence". The famous medical physiologist Dr. W.B. Cannon wrote a highly acclaimed book entitled "The Wisdom of the Body" that the main task of the wisdom of the body is to improve and maintain the quantity of health. This is accomplished through control processes that are even more intricate than the feedback auto-regulatory controls of homeostasis but cannot be expressed by physiochemical laws and equations.
Generally today, instead of testing how intelligent the immune system is, our current technology allows us to merely measure the potency of some of its weapons. The writer's believe this is a critical flaw in most of today's research.

In-vitro studies that are so commonly performed rarely have any useful clinical application. At the same time, experimental data on various uniquely created herbal extracts described as immuno-modulating compounds created by different research groups that, owing to their nature, are all but impossible to integrate into a comprehensive therapeutic protocol.

Previously presented clinical research papers demonstrate that the immune system is a dynamic multidimensional system that can help sustain us using a variety of strategies. Evolutionary biochemistry has imbued our immune system with several overlapping protective tactics that can at least partially replace one another.

To presuppose that administering a single biochemical substance with static immuno-modulatory effects to correct an immune deficiency will work reproducibly well in most patients appears short sighted and naive. In fact, such substances administered in this manner will generally only undermine the potential good that the agent may do in the long run if properly balanced and supported.

Ai/E\(^{10}\) is the first of a new type of immuno-modulator produced by a living mammal for other living mammals and has unique dynamic elements that appear to provide a wide range of immunological benefits. The implications of widespread use of an immuno-modulator such as that examined herein would have an enormous impact on the general health of a population such as that in the United States where immune suppression by lifestyle is an inherent factor in the nature of the culture at this time. Improvement in immune performance as experienced by the study group that utilized Ai/E\(^{10}\) would result in a reduction in dependence upon prescription medications ranging from antibiotics to antidepressants and an improved ability to cope with the stresses of everyday life.

**Appendix 1**

Blood tests examined for all participants:
- T & B Cell Subset
- Natural Killer Cell Function
- Eosinophilic Cationic Protein
- TNF
- Phagocytic Index
- IL-2r
- IL-6a-INF
Appendix 2

Statistical Summary

**Group A**

<table>
<thead>
<tr>
<th></th>
<th>TNF Before</th>
<th>TNF After</th>
<th>NK Before</th>
<th>NK After</th>
<th>PI Before</th>
<th>PI After</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3.9</td>
<td>4.6</td>
<td>132</td>
<td>89</td>
<td>2.2</td>
<td>2.5</td>
</tr>
<tr>
<td>2</td>
<td>3.9</td>
<td>4.4</td>
<td>56</td>
<td>100</td>
<td>3.9</td>
<td>5.0</td>
</tr>
<tr>
<td>3</td>
<td>3.9</td>
<td>6.1</td>
<td>103</td>
<td>46</td>
<td>2.7</td>
<td>4.7</td>
</tr>
<tr>
<td>4</td>
<td>4.1</td>
<td>8.8</td>
<td>169</td>
<td>46</td>
<td>2.3</td>
<td>2.0</td>
</tr>
<tr>
<td>5</td>
<td>3.9</td>
<td>3.9</td>
<td>23</td>
<td>95</td>
<td>2.7</td>
<td>5.1</td>
</tr>
<tr>
<td>6</td>
<td>3.9</td>
<td>4.2</td>
<td>10</td>
<td>38</td>
<td>2.7</td>
<td>4.4</td>
</tr>
<tr>
<td>7</td>
<td>6.8</td>
<td>9.7</td>
<td>44</td>
<td>54</td>
<td>3.6</td>
<td>3.4</td>
</tr>
<tr>
<td>8</td>
<td>3.9</td>
<td>4.4</td>
<td>52</td>
<td>53</td>
<td>2.6</td>
<td>3.1</td>
</tr>
<tr>
<td>9</td>
<td>3.9</td>
<td>3.9</td>
<td>27</td>
<td>65</td>
<td>3.9</td>
<td>4.3</td>
</tr>
<tr>
<td>10</td>
<td>3.9</td>
<td>3.9</td>
<td>72</td>
<td>184</td>
<td>4.9</td>
<td>4.9</td>
</tr>
</tbody>
</table>

**Group B**

<table>
<thead>
<tr>
<th></th>
<th>TNF Before</th>
<th>TNF After</th>
<th>NK Before</th>
<th>NK After</th>
<th>PI Before</th>
<th>PI After</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6.1</td>
<td>7.6</td>
<td>66</td>
<td>69</td>
<td>2.8</td>
<td>2.4</td>
</tr>
<tr>
<td>2</td>
<td>3.9</td>
<td>3.9</td>
<td>22</td>
<td>74</td>
<td>4.6</td>
<td>7.6</td>
</tr>
<tr>
<td>3</td>
<td>3.9</td>
<td>4.1</td>
<td>32</td>
<td>45</td>
<td>3.2</td>
<td>2.6</td>
</tr>
<tr>
<td>4</td>
<td>3.9</td>
<td>3.9</td>
<td>92</td>
<td>34</td>
<td>3.3</td>
<td>5.2</td>
</tr>
<tr>
<td>5</td>
<td>5.0</td>
<td>3.9</td>
<td>145</td>
<td>135</td>
<td>2.1</td>
<td>7.6</td>
</tr>
<tr>
<td>6</td>
<td>4.2</td>
<td>6.5</td>
<td>42</td>
<td>118</td>
<td>3.3</td>
<td>3.1</td>
</tr>
<tr>
<td>7</td>
<td>3.9</td>
<td>3.9</td>
<td>49</td>
<td>49</td>
<td>2.6</td>
<td>2.1</td>
</tr>
<tr>
<td>8</td>
<td>3.9</td>
<td>4.7</td>
<td>35</td>
<td>31</td>
<td>4.1</td>
<td>4.2</td>
</tr>
<tr>
<td>9</td>
<td>11.0</td>
<td>6.7</td>
<td>125</td>
<td>38</td>
<td>4.2</td>
<td>5.3</td>
</tr>
<tr>
<td>10</td>
<td>3.9</td>
<td>4.8</td>
<td>438</td>
<td>29</td>
<td>3.8</td>
<td>3.0</td>
</tr>
</tbody>
</table>

References